Systematic review

Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials

Jimmy Wen et al. · Cureus · 2024

Evidence type: Systematic review Interpretive weight: LimitedResearch area: Physical performance and safety
DesignPRISMA-guided systematic review of randomized controlled trials
PopulationAdults in randomized NMN supplementation trials
Sample10 studies; 437 participants
InterventionNMN 150–1,200 mg/day; mean follow-up 9.6 weeks
EndpointsGrip strength; Skeletal mass index; Other physical-performance measures; Adverse events

What the publication reported

This systematic review examined ten randomized NMN studies involving 437 participants and focused on physical performance and safety.

Average grip strength and skeletal-mass-index values changed only modestly, and the review described physical-performance improvements as non-significant overall.

No serious adverse effects were identified in the included trials, but the available trials were short and heterogeneous.

Key findings

  • Ten randomized studies and 437 participants were included.
  • NMN doses ranged from 150 to 1,200 mg/day.
  • Physical-performance parameters showed non-significant improvement overall.
  • No serious adverse effects were observed in the included trials.

What it cannot establish

  • The included trials used different performance tests, doses and populations.
  • Many individual performance outcomes were available from only a few studies.
  • Follow-up was short, averaging under 10 weeks.
  • Absence of serious adverse events in small short trials does not establish long-term safety.
HealthspanX claim boundary: This review does not establish that NMN improves strength, muscle mass or physical performance across adults.

Continue reviewing

Return to the complete evidence library.

Evidence Center Ultra Pure NMN

Source fields verified